{"id":"https://openalex.org/W2566060809","doi":"https://doi.org/10.1182/blood.v124.21.1874.1874","title":"Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis","display_name":"Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis","publication_year":2014,"publication_date":"2014-12-06","ids":{"openalex":"https://openalex.org/W2566060809","doi":"https://doi.org/10.1182/blood.v124.21.1874.1874","mag":"2566060809"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v124.21.1874.1874","doi":"https://doi.org/10.1182/blood.v124.21.1874.1874","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.1874.1874","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071375525","display_name":"Jack W. Singer","orcid":"https://orcid.org/0000-0003-4001-4549","observed_orcids":["https://orcid.org/0000-0003-4001-4549"]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jack Singer","raw_affiliation_strings":["CTI BioPharma, Corp, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CTI BioPharma, Corp, Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005050727","display_name":"Suliman Al\u2010Fayoumi","orcid":"https://orcid.org/0000-0001-9372-8145","observed_orcids":["https://orcid.org/0000-0001-9372-8145"]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Suliman Al-Fayoumi","raw_affiliation_strings":["CTI Biopharma, Corp, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CTI Biopharma, Corp, Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102439525","display_name":"Haiching Ma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103473","display_name":"Reaction Biology Corporation (United States)","ror":"https://ror.org/01ada6a49","country_code":"US","type":"company","lineage":["https://openalex.org/I4210103473"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Haiching Ma","raw_affiliation_strings":["Reaction Biology, Malvern, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Reaction Biology, Malvern, PA","institution_ids":["https://openalex.org/I4210103473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010075752","display_name":"Rami S. Komrokji","orcid":"https://orcid.org/0000-0002-1876-5269","observed_orcids":["https://orcid.org/0000-0002-1876-5269"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rami S Komrokji","raw_affiliation_strings":["H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben Mesa","raw_affiliation_strings":["Mayo Clinic Cancer Center, Scottsdale, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Cancer Center, Scottsdale, AZ","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5005050727","https://openalex.org/A5102439525"],"corresponding_institution_ids":["https://openalex.org/I4210101701","https://openalex.org/I4210103473"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":1.9407,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.87797034,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"124","issue":"21","first_page":"1874","last_page":"1874"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.8840000033378601},{"id":"https://openalex.org/keywords/essential-thrombocythemia","display_name":"essential thrombocythemia","score":0.9430000185966492},{"id":"https://openalex.org/keywords/primary-myelofibrosis","display_name":"primary myelofibrosis","score":0.9200000166893005},{"id":"https://openalex.org/keywords/kinase-profiling","display_name":"kinase profiling","score":0.4830000102519989},{"id":"https://openalex.org/keywords/jak2-v617f-mutation","display_name":"JAK2 V617F mutation","score":0.8320000171661377},{"id":"https://openalex.org/keywords/flt3","display_name":"FLT3","score":0.6779999732971191},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibition","display_name":"tyrosine kinase inhibition","score":0.6790000200271606},{"id":"https://openalex.org/keywords/spleen-size-reduction","display_name":"spleen size reduction","score":0.8370000123977661},{"id":"https://openalex.org/keywords/platelet-count","display_name":"platelet count","score":0.7179999947547913},{"id":"https://openalex.org/keywords/c-kit","display_name":"CD117","score":0.47600001096725464},{"id":"https://openalex.org/keywords/src-kinase","display_name":"Src kinase","score":0.7799999713897705},{"id":"https://openalex.org/keywords/jak3","display_name":"JAK3","score":0.4749999940395355}],"concepts":[{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8492653369903564},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.6374750137329102},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.6358053684234619},{"id":"https://openalex.org/C54174078","wikidata":"https://www.wikidata.org/wiki/Q3197188","display_name":"Kinome","level":3,"score":0.5864886045455933},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.570487916469574},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5550671219825745},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.4828374981880188},{"id":"https://openalex.org/C2910274570","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative Disorders","level":2,"score":0.43295568227767944},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.36503615975379944},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24436846375465393},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.22849929332733154},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12113487720489502}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v124.21.1874.1874","doi":"https://doi.org/10.1182/blood.v124.21.1874.1874","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.1874.1874","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2514287253","https://openalex.org/W2503725641","https://openalex.org/W4392108373","https://openalex.org/W2945289622","https://openalex.org/W2029985592","https://openalex.org/W4386071127","https://openalex.org/W7097122961","https://openalex.org/W4379282483","https://openalex.org/W4353070780","https://openalex.org/W2884593313"],"abstract_inverted_index":{"Abstract":[0],"BackgroundPacritinib,":[1],"a":[2,125],"JAK2,":[3,371],"JAK2":[4,282],"V617F":[5],"and":[6,20,29,51,86,93,113,224,299,305,362,373],"FLT3":[7,200],"kinase":[8,216,322,349],"inhibitor":[9],"is":[10,326],"in":[11,15,21,25,39,53,64,69,99,109,187,262,310,330,359,364],"Phase":[12,22,66],"III":[13],"development":[14,331],"myelofibrosis.":[16],"In":[17,159],"preclinical":[18],"models":[19,312],"1":[23],"studies":[24,68],"both":[26],"non-Hodgkin":[27],"lymphoma":[28],"myelofibrosis,":[30],"it":[31],"appeared":[32],"unique":[33,327],"among":[34,328],"this":[35],"class":[36],"of":[37,42,89,123,168,183,251,271,281,289,307,336,338,342,352,370],"agents":[38,329],"its":[40,355],"lack":[41,122,270,335],"myelosuppression":[43,272],"at":[44,82,133,151,171,246],"doses":[45],"that":[46,71,147,268],"inhibited":[47,150],"the":[48,118,172,188,249,259,263,269,302,348],"JAK2/STAT3":[49],"pathway":[50],"resulted":[52],"significant":[54],"clinical":[55,60],"efficacy.":[56],"This":[57],"potentially":[58],"important":[59],"observation":[61],"was":[62,80,95,138],"verified":[63],"two":[65],"II":[67],"myelofibrosis":[70,333],"had":[72],"no":[73,96],"exclusion":[74],"restriction":[75],"for":[76,120,217,324,332],"low":[77],"platelets.":[78],"Pacritinib":[79],"effective":[81],"reducing":[83],"spleen":[84],"size":[85],"symptoms":[87],"regardless":[88],"starting":[90],"platelet":[91,101],"counts":[92],"there":[94],"apparent":[97],"decline":[98],"either":[100,277],"count":[102],"or":[103,106,286],"hemoglobin":[104],"levels,":[105],"an":[107,291],"increase":[108],"transfusion":[110],"requirements.":[111],"Aims":[112],"Methods:":[114],"To":[115],"help":[116],"elucidate":[117],"mechanisms":[119],"pacritinib\u2019s":[121],"myelosuppression,":[124],"kinome":[126],"screening":[127],"analysis":[128],"against":[129,145],"429":[130],"recombinant":[131],"kinases":[132,179,260],"100":[134],"nM":[135],"pacritinib":[136,161,239,252,274,325,353],"concentration":[137],"performed,":[139],"followed":[140],"by":[141],"titration":[142],"from":[143,296],"1-100nM":[144],"those":[146],"were":[148],">50%":[149],"100nM":[152],"(Anastassiadis":[153],"et":[154,314],"al.;":[155,315],"Nature":[156],"Biotechnology;":[157],"2011).":[158],"humans,":[160],"achieves":[162],"steady":[163],"state":[164],"free":[165],"drug":[166],"levels":[167],"approximately":[169],"200nM":[170],"standard":[173],"400":[174],"mg":[175],"daily":[176],"dose.":[177],"Results:All":[178],"with":[180,273,301,340],"IC50":[181,192],"values":[182],"<50nM":[184],"are":[185,255],"included":[186],"table.":[189],"Table":[190],"Kinase":[191],"(nM)":[193],"JAK2;":[194],"JAK2(V617F)":[195],"6.0;":[196],"9.4":[197],"FLT3;":[198],"FLT3-ITD;":[199],"(D835Y)":[201],"6.4;":[202],"12.0;":[203],"8.3":[204],"TYK2":[205],"27.0":[206],"JAK3":[207],"18.3":[208],"IRAK1":[209],"(IL-1":[210],"receptor":[211,293],"kinase)":[212],"13.6":[213],"HIPK4":[214],"(PT":[215],"P53":[218],"ser-9)":[219],"14.5":[220],"FMS":[221],"39.5":[222],"c-KIT":[223],"most":[225],"common":[226],"mutations":[227],"except":[228],"(V560G),":[229],"(V559D/V654A)":[230],"43.8":[231],"c-Src;":[232],"(c-Src":[233],"(T341M))":[234],"47.0":[235],"(55.5)":[236],"Of":[237],"note,":[238],"did":[240],"not":[241],"affect":[242],"JAK1":[243,285,339],"(82%":[244],"control":[245],"100nM).":[247],"As":[248],"concentrations":[250],"achieved":[253],"clinically":[254],"likely":[256],"inhibit":[257],"signaling":[258,344],"listed":[261],"table,":[264],"these":[265],"data":[266],"suggest":[267],"may":[275],"be":[276],"due":[278,366],"to":[279,287,367],"inhibition":[280,350],"without":[283],"affecting":[284],"suppression":[288,306,337,341],"IRAK1,":[290],"IL-1":[292],"kinase,":[294],"downstream":[295],"Toll-Like":[297],"Receptors,":[298],"associated":[300],"inflammatory":[303,343],"response":[304],"normal":[308],"hematopoiesis":[309],"myelodysplasia":[311],"(Rhyasen":[313],"Cancer":[316],"Cell;":[317],"24:90,":[318],"2013).":[319],"Conclusions:":[320],"The":[321],"profile":[323,351],"combining":[334],"through":[345],"IRAK1.":[346,374],"Moreover,":[347],"suggests":[354],"potential":[356],"therapeutic":[357],"utility":[358],"AML,":[360],"MDS,":[361],"particularly":[363],"CMML":[365],"CMML\u2019s":[368],"upregulation":[369],"c-FMS,":[372],"Disclosures":[375],"Singer:":[376],"CTI":[377],"BioPharma,":[378,396],"Corp:":[379,397],"Employment,":[380],"Equity":[381],"Ownership.":[382],"Mesa:Incyte":[383],"Corporation,":[384],"CTI,":[385],"NS":[386],"Pharma,":[387],"Inc.,":[388,391],"Gilead":[389],"Science":[390],"Celgene:":[392],"Research":[393,398],"Funding.":[394,399],"Verstovsek:CTI":[395]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-01-06T00:00:00"}